Today’s Stock Alert: Is Valeant Pharmaceuticals Intl Inc’s Fuel Running Low? The Stock Just Declined Again

Today's Stock Alert: Is Valeant Pharmaceuticals Intl Inc's Fuel Running Low? The Stock Just Declined Again

The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is a huge mover today! About 30.95 million shares traded hands or 35.92% up from the average. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has declined 50.86% since April 27, 2016 and is downtrending. It has underperformed by 56.09% the S&P500.
The move comes after 7 months negative chart setup for the $5.28 billion company. It was reported on Nov, 30 by We have $14.64 PT which if reached, will make NYSE:VRX worth $369.60 million less.

Analysts await Valeant Pharmaceuticals Intl Inc (NYSE:VRX) to report earnings on March, 21. They expect $1.34 EPS, down 46.61% or $1.17 from last year’s $2.51 per share. VRX’s profit will be $449.79 million for 2.93 P/E if the $1.34 EPS becomes a reality. After $1.55 actual EPS reported by Valeant Pharmaceuticals Intl Inc for the previous quarter, Wall Street now forecasts -13.55% negative EPS growth.

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Ratings Coverage

Out of 23 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 8 rate it a “Buy”, 3 “Sell”, while 12 “Hold”. This means 35% are positive. Valeant Pharmaceuticals Intl has been the topic of 80 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The rating was downgraded by Mizuho on Wednesday, November 23 to “Underperform”. As per Friday, November 6, the company rating was maintained by Guggenheim. The firm earned “Hold” rating on Monday, November 14 by Deutsche Bank. The firm has “Buy” rating given on Friday, October 30 by UBS. The firm earned “Hold” rating on Wednesday, March 2 by Canaccord Genuity. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) earned “Underperform” rating by Wells Fargo on Friday, February 19. On Friday, October 14 the stock rating was maintained by Deutsche Bank with “Hold”. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has “Neutral” rating given on Thursday, January 7 by Mizuho. Rodman & Renshaw maintained Valeant Pharmaceuticals Intl Inc (NYSE:VRX) rating on Wednesday, March 16. Rodman & Renshaw has “Buy” rating and $118 price target. Scotia Capital maintained it with “Sector Outperform” rating and $250 target price in Tuesday, October 20 report.

According to Zacks Investment Research, “Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant’s development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.”

Insitutional Activity: The institutional sentiment increased to 0.88 in 2016 Q2. Its up 0.02, from 0.86 in 2016Q1. The ratio increased, as 88 funds sold all Valeant Pharmaceuticals Intl Inc shares owned while 97 reduced positions. 52 funds bought stakes while 107 increased positions. They now own 217.59 million shares or 18.89% less from 268.27 million shares in 2016Q1.
Moreover, Clinton Group has 0.16% invested in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 176,927 shares. Camber Limited Co reported 1.66 million shares or 1.61% of all its holdings. Global X Mgmt Co Ltd Liability Company has 903 shares for 0% of their US portfolio. Moreover, Kemnay Advisory has 0.01% invested in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 690 shares. Franklin Street Advsr Inc Nc reported 18,470 shares or 0.07% of all its holdings. Financial Corp accumulated 0% or 20 shares. Douglass Winthrop Advisors Limited Com has invested 1.66% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Bluefin Trading Lc has invested 0.06% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Moreover, Amer International Group Incorporated has 0% invested in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 4,200 shares. Continental Advisors Ltd holds 0.59% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 95,600 shares. Stoneridge Investment Prns Ltd Limited Liability Company, a Pennsylvania-based fund reported 138,637 shares. Natl Bank Of Montreal Can accumulated 3.45 million shares or 0.08% of the stock. Ct Mason owns 12,517 shares or 0.11% of their US portfolio. Bloombergsen holds 0% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 66 shares. Brave Asset Mngmt has invested 0.01% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX).

Insider Transactions: Since June 9, 2016, the stock had 2 insider buys, and 0 selling transactions for $5.04 million net activity. PAPA JOSEPH C bought $4.94M worth of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) on Thursday, June 9. Another trade for 4,000 shares valued at $98,600 was made by KARABELAS ARGERIS N on Thursday, August 11.

More notable recent Valeant Pharmaceuticals Intl Inc (NYSE:VRX) news were published by: which released: “Valeant Announces The Initiation Of A Primary Care Sales Force For Xifaxan …” on November 29, 2016, also with their article: “Valeant Pharmaceuticals Intl Inc: More Bad News for VRX Stock” published on November 24, 2016, published: “3 Figures in Focus When Valeant Pharmaceuticals Intl. Inc. Reports Its Q3 Results” on November 01, 2016. More interesting news about Valeant Pharmaceuticals Intl Inc (NYSE:VRX) were released by: and their article: “Valeant Pharmaceuticals Intl Inc: VRX Stock Rises Again” published on November 10, 2016 as well as‘s news article titled: “Valeant Pharmaceuticals Intl Inc: Did VRX Stock Just Bottom?” with publication date: November 03, 2016.

VRX Company Profile

Valeant Pharmaceuticals International, Inc., incorporated on August 9, 2013, is a specialty pharmaceutical and medical device company. The Firm is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Firm operates through two divisions: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal (GI) disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses primarily on branded generics, OTC products and medical devices.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment